170 related articles for article (PubMed ID: 28233244)
1. Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells.
Li F; Mei H; Xie X; Zhang H; Liu J; Lv T; Nie H; Gao Y; Jia L
AAPS J; 2017 May; 19(3):814-826. PubMed ID: 28233244
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer.
Li F; Mei H; Gao Y; Xie X; Nie H; Li T; Zhang H; Jia L
Biomaterials; 2017 Nov; 145():56-71. PubMed ID: 28843733
[TBL] [Abstract][Full Text] [Related]
3. Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy.
Saravanakumar K; Sathiyaseelan A; Mariadoss AVA; Jeevithan E; Hu X; Shin S; Wang MH
Carbohydr Polym; 2020 Oct; 245():116407. PubMed ID: 32718591
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy.
Chen Z; Tai Z; Gu F; Hu C; Zhu Q; Gao S
Eur J Pharm Biopharm; 2016 Oct; 107():130-41. PubMed ID: 27393562
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
8. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.
Suda K; Mizuuchi H; Sato K; Takemoto T; Iwasaki T; Mitsudomi T
Int J Cancer; 2014 Aug; 135(4):1002-6. PubMed ID: 24458568
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
11. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
[TBL] [Abstract][Full Text] [Related]
12. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
Ara MN; Matsuda T; Hyodo M; Sakurai Y; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2014 Aug; 35(25):7110-20. PubMed ID: 24875764
[TBL] [Abstract][Full Text] [Related]
13. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
16. Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy.
Pardeshi S; Tiwari A; Titame U; Singh PK; Yadav PK; Chourasia MK
J Liposome Res; 2022 Dec; 32(4):386-395. PubMed ID: 35225132
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
Masuda C; Yanagisawa M; Yorozu K; Kurasawa M; Furugaki K; Ishikura N; Iwai T; Sugimoto M; Yamamoto K
Int J Oncol; 2017 Aug; 51(2):425-434. PubMed ID: 28627678
[TBL] [Abstract][Full Text] [Related]
18. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
19. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
[TBL] [Abstract][Full Text] [Related]
20. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
Sayari E; Dinarvand M; Amini M; Azhdarzadeh M; Mollarazi E; Ghasemi Z; Atyabi F
Int J Pharm; 2014 Oct; 473(1-2):304-15. PubMed ID: 24905777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
